Bristol Myers Gets EC Approval for Onureg in Acute Myeloid Leukemia

By Michael Dabaie

Bristol Myers Squibb said the European Commission granted full marketing authorization for Onureg as a maintenance therapy in acute myeloid leukemia.

Bristol Myers said the authorization approves use of Onureg in all European Union member states, as well as Norway, Iceland and Liechtenstein.

In the pivotal QUAZAR AML-001 study, Onureg significantly improved overall survival and relapse-free survival in patients with acute myeloid leukemia, the company said.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

06-18-21 1008ET